oAlert.pl

Medicines & supplements – Current GIS Alerts 2026

Found 735 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Recalled product: ELOFEN

ELOFEN

GIF Medium 11.02.2019
Recalled product: BENODIL

BENODIL

GIF High 07.02.2019

Out-of-specification results for related substances of budesonide. Potential effects: reduced efficacy or altered safety of use.

Recalled product: BUDIXON NEB

BUDIXON NEB

GIF High 07.02.2019

Test results out of specification in archival samples concerning the content of budesonide related substances. Potential effects: reduced efficacy, increased risk of adverse reactions.

Recalled product: BDS N

BDS N

GIF High 07.02.2019

Out-of-specification results for the content of related substances of budesonide. Potential effects: reduced efficacy or safety of the medicinal product.

Recalled product: BENODIL

BENODIL

GIF Medium 07.02.2019

Test results out of specification: elevated related substances content of budesonide. Potential effects: reduced efficacy, increased risk of adverse reactions.

Recalled product: BUDIXON NEB

BUDIXON NEB

GIF Medium 07.02.2019

Out-of-specification results for the content of budesonide-related substances. Potential effects: reduced efficacy or increased risk of adverse reactions.

Recalled product: LOREBLOK HCT

LOREBLOK HCT

GIF Critical 01.02.2019

Detection of contamination: N-nitroso-N-methylamino-butyric acid (NMBA) in the active substance losartan. Potential effects: long-term carcinogenic risk.

Recalled product: LOREBLOK

LOREBLOK

GIF Critical 01.02.2019

Contamination with N-nitroso-N-methylamino butyric acid (NMBA) was detected in some batches of the losartan active substance (from Hetero Labs Limited). Potential effects: increased risk of carcinogenic effects with long-term exposure.

Recalled product: APO-LOZART

APO-LOZART

GIF Critical 01.02.2019

Detected contamination with N-nitroso-N-methylamino butyric acid (NMBA) in some batches of the losartan potassium active substance. Potential effects: carcinogenicity, increased long-term health risk.

Recalled product: APO-LOZART

APO-LOZART

GIF Critical 01.02.2019

Detected contamination of the active substance with N-nitroso-N-methylamino-butyric acid (NMBA), an N-nitrosamine that may affect human health and life. Potential effects: increased cancer risk, systemic toxic effects.

Recalled product: SYDAFED XYLOSPRAY HA

SYDAFED XYLOSPRAY HA

GIF Critical 25.01.2019

It cannot be excluded that the product batch fails to meet quality requirements regarding sterility. Potential effects: risk of infections or other health complications.

Recalled product: IRPRESTAN

IRPRESTAN

GIF Critical 24.01.2019

Detection of N-nitrosodiethylamine (NDEA) above the acceptable limit in the active substance sourced from Zhejiang Huahai. Potential effects: carcinogenic action and long-term health risk.

Recalled product: PECFENT

PECFENT

GIF Critical 18.01.2019

Suspected defect in the primary packaging of the PecFent batch, potentially causing loss of seal/integrity. Potential effects: incorrect dose (evaporation of solution), risk to health and life.

Recalled product: XALOPTIC FREE

XALOPTIC FREE

GIF Medium 14.01.2019

Does not meet specification: elevated impurity content — 15(5)-latanoprost, single unknown impurities and increased sum of unknown and total impurities. Potential effects: risk of adverse reactions or reduced efficacy.

Recalled product: FLUCINAR N

FLUCINAR N

GIF High 04.01.2019

Out-of-specification result in a reference sample — impurities originating from fluocinolone acetonide. Potential effects: reduced efficacy, skin adverse effects (irritation, allergic reactions).

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.